Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors
Cartography Biosciences has appointed Troy E. Wilson, Ph.D., J.D. as an independent director to its Board of Directors. Wilson, a 25-year biopharma industry veteran, is currently President, CEO, and co-founder of Kura Oncology (NASDAQ: KURA). He brings extensive experience in founding and leading biotech companies, including Avidity Biosciences, Araxes Pharma, and Wellspring Biosciences. Cartography, an oncology company developing antibody therapeutics, aims to leverage Wilson's expertise as it advances its pipeline of novel programs targeting tumors more precisely than existing treatments.
Cartography Biosciences ha nominato Troy E. Wilson, Ph.D., J.D. come direttore indipendente nel suo Consiglio di Amministrazione. Wilson, un esperto del settore biopharma con 25 anni di esperienza, è attualmente Presidente, CEO e co-fondatore di Kura Oncology (NASDAQ: KURA). Porta con sé una vasta esperienza nella fondazione e nella direzione di aziende biotecnologiche, tra cui Avidity Biosciences, Araxes Pharma e Wellspring Biosciences. Cartography, un'azienda oncologica che sviluppa terapie a base di anticorpi, mira a sfruttare l'expertise di Wilson mentre avanza nel suo progetto di nuovi programmi volti a colpire i tumori in modo più preciso rispetto ai trattamenti esistenti.
Cartography Biosciences ha nombrado a Troy E. Wilson, Ph.D., J.D. como director independiente en su Junta Directiva. Wilson, un veterano de 25 años en la industria biopharma, es actualmente Presidente, CEO y cofundador de Kura Oncology (NASDAQ: KURA). Aporta una amplia experiencia en la fundación y dirección de empresas biotecnológicas, incluyendo Avidity Biosciences, Araxes Pharma y Wellspring Biosciences. Cartography, una empresa oncológica que desarrolla terapias con anticuerpos, tiene como objetivo aprovechar la experiencia de Wilson mientras avanza en su cartera de nuevos programas que apuntan a tumores con mayor precisión que los tratamientos existentes.
Cartography Biosciences는 Troy E. Wilson, Ph.D., J.D.를 이사회의 독립 이사로 임명했습니다. Wilson은 25년의 바이오제약 산업 경험을 가진 전문가로, 현재 Kura Oncology (NASDAQ: KURA)의 사장, CEO 및 공동 설립자입니다. 그는 Avidity Biosciences, Araxes Pharma 및 Wellspring Biosciences와 같은 생명공학 회사를 설립하고 이끌었던 광범위한 경험을 보유하고 있습니다. 항체 치료제를 개발하는 온콜로지 회사인 Cartography는 기존 치료법보다 더 정밀하게 종양을 표적으로 하는 새로운 프로그램의 파이프라인을 발전시키면서 Wilson의 전문 지식을 활용할 계획입니다.
Cartography Biosciences a nommé Troy E. Wilson, Ph.D., J.D. en tant que directeur indépendant au sein de son Conseil d'Administration. Wilson, un vétéran de l'industrie biopharmaceutique avec 25 ans d'expérience, est actuellement Président, CEO et co-fondateur de Kura Oncology (NASDAQ: KURA). Il apporte une vaste expérience dans la création et la direction d'entreprises biotechnologiques, y compris Avidity Biosciences, Araxes Pharma et Wellspring Biosciences. Cartography, une société d'oncologie développant des thérapies par anticorps, vise à tirer parti de l'expertise de Wilson alors qu'elle fait progresser son pipeline de nouveaux programmes ciblant les tumeurs de manière plus précise que les traitements existants.
Cartography Biosciences hat Troy E. Wilson, Ph.D., J.D. als unabhängigen Direktor in seinen Vorstand berufen. Wilson, ein 25-jähriger Veteran der Biopharma-Industrie, ist derzeit Präsident, CEO und Mitgründer von Kura Oncology (NASDAQ: KURA). Er bringt umfangreiche Erfahrung in der Gründung und Leitung von Biotech-Unternehmen mit, darunter Avidity Biosciences, Araxes Pharma und Wellspring Biosciences. Cartography, ein Unternehmen, das onkologische Antikörpertherapien entwickelt, beabsichtigt, Wilsons Fachwissen zu nutzen, während es sein Portfolio neuartiger Programme vorantreibt, die Tumoren präziser anvisieren als bestehende Behandlungen.
- Appointment of highly experienced industry veteran with 25 years in biopharma
- Wilson's track record includes successful exits and acquisitions of multiple biotech companies
- Strategic addition to strengthen board expertise during company's growth phase
- None.
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline -
“We are delighted to have attracted a true industry luminary in Troy Wilson to the Cartography board,” said Kevin Parker, Ph.D., CEO of Cartography Biosciences. “His extensive track record of success will prove invaluable as we move into a critical and exciting period of scientific advances, operational growth and accelerating clinical activity. Troy founded or co-founded multiple biotech companies and led those organizations through the stages of formation, clinical strategy development, rapid growth and commercialization. He has also been central to the successful exits of multiple biopharma organizations. We couldn’t ask for a more qualified director, and I am personally looking forward to benefiting from his executive insights and governance acumen.”
“Cartography is doing important work to discover and develop novel therapies for patients with cancer,” said Dr. Wilson. “With so many companies crowding into a handful of established targets, new therapeutic targets are urgently needed, and Cartography is doing truly pioneering work to deliver new treatment options. Cartography’s approach, using its single-cell atlases to identify cell specific targets and target pairs, is an exciting one with the potential to develop effective targeted therapies with fewer risks to healthy cells and tissues. To that end, I am pleased to join the board as an independent director, and I look forward to working with Kevin and the team as they advance their pipeline of novel programs into the clinic.”
Dr. Wilson is a serial entrepreneur with a passion to build exceptional companies that create significant value for patients, employees and shareholders. Prior to Kura, he co-founded and served as President and CEO of Avidity Biosciences (NASDAQ: RNA) where he has served as chairman of its board of directors since inception. He also co-founded and served as President and CEO of Araxes Pharma LLC and Wellspring Biosciences, where his team pioneered the discovery and development of KRAS G12C selective small molecule inhibitors. Earlier in his career, Dr. Wilson co-founded and served as President and CEO of Intellikine, a private biopharmaceutical company, acquired by Takeda Pharmaceutical Company Limited in 2011, and he co-founded and served as chief business officer of Ambrx (NASDAQ: AMAM), acquired by Johnson & Johnson Innovative Medicines in 2024. He has also been a member of the Board of Directors of Puma Biotechnology, Inc., a publicly held biopharmaceutical company, since October 2013.
Dr. Wilson holds a J.D. from
About Cartography Biosciences
Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. Cartography’s ATLAS and SUMMIT drug discovery platforms are powered by an industry-leading, fully integrated dataset spanning over a thousand cell types across the healthy body and large-scale profiling of individual cells from patient tumors. By leveraging petabytes of proprietary data, along with insights from machine learning and AI, Cartography is identifying and developing therapeutics against highly specific targets and target pairs to build a pipeline of molecules with the greatest patient impact. Cartography’s lead program in preclinical development, CB21, is a T-cell engager being advanced for colorectal cancer (CRC). To learn more about Cartography and our mission to treat every patient with cancer, visit cartography.bio and follow us on LinkedIn and X @cartographybio.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029358268/en/
Media:
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
(704) 488-7369
Source: Cartography Biosciences, Inc.
FAQ
Who is the new board member appointed to Cartography Biosciences?
What is Troy Wilson's experience in the biotech industry?
What is Cartography Biosciences' main business focus?
